Joe Kennedy Daniel Castro December 17, 2013
December 17, 2013

The controversy over the FDA’s recent letter ordering the genetic testing company 23andMe to stop marketing its services for failure to comply with the agency’s regulatory process suggests that the prognosis for direct-to-consumer health services, particularly genetic testing, is quite uncertain. Given the enormous potential benefits to consumers, this is unfortunate.